SG
AKBA icon

StoneX Group’s Akebia Therapeutics AKBA Stock Holding History

StoneX Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,440
Closed -$3.3K – 590
2022
Q3 		$3.3K Sell
10,440
-4,660
-31% -$1.83K ﹤0.01% 327
2022
Q2 		$5.33K Buy
+15,100
New +$6.34K ﹤0.01% 480

Other funds holding AKBA

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCM
Ovata Capital Management Hong Kong $715M AUM 19.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

StoneX Group's AKBA Position: Q4 2022 in Review

StoneX Group sold out of Akebia Therapeutics (AKBA) in Q4 2022, closing a stake of 10,440 shares — an estimated $3.3K sold.

StoneX Group first reported a position in AKBA in Q2 2022 and held it in 2 quarters. The position peaked at $5.33K in Q2 2022. 75 funds tracked by Wall St. Rank hold AKBA as of Q4 2022.

  • StoneX Group reported no remaining Akebia Therapeutics position as of Q4 2022 after selling out during the quarter.
  • StoneX Group sold 10,440 Akebia Therapeutics shares in Q4 2022, an estimated $3.3K.
  • StoneX Group first reported a position in Akebia Therapeutics in Q2 2022 and held it in 2 quarters.
  • StoneX Group's Akebia Therapeutics position peaked at $5.33K in Q2 2022.
  • 75 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2022.

Based on StoneX Group's 13F filing for Q4 2022, filed 10 Feb 2023.